Study:
Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH
Rationale:
n/a
Purpose:
The purpose of this study is to see whether droxidopa is effective in treating symptoms of
neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure
Autonomic Failure, Multiple System Atrophy, Parkinson`s Disease), Non-diabetic neuropathy,
or Beta Hydroxylase deficiency.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Symptomatic Neurogenic Orthostatic Hypotension (NOH)
Non-diabetic Neuropathy
Primary Autonomic Failure
Dopamine Beta Hydroxylase Deficiency |
Drug: Placebo
Drug: Droxidopa |
Phase 3 |
Verified by
Chelsea Therapeutics
March, 2013
Sponsored by: Chelsea Therapeutics
Information provided by: Chelsea Therapeutics
ClinicalTrials.gov identifier: NCT00633880
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
Horacio Kaufmann, MD., Principal Investigator
Christopher J Mathias, MD., Principal Investigator
Roy Freeman, MD., Principal Investigator
Phillip A Low, MD., Principal Investigator